While additional research is needed to determine how GLP-1 RAs put a person at an increased risk for NAION, it may be linked to fluctuations in blood pressure and blood sugar, diabetes-related vascular issues, and low blood sugar (hypoglycemia) caused by Mounjaro
Retatrutide-Specific Considerations The Phase 2 trial for retatrutide reported higher rates of gastrointestinal side effects at upper dose levels compared to tirzepatide, which may be attributed to the additional glucagon receptor activation
While the FDA labels acknowledge reports of acute gallbladder disease, they do not establish definitive causation, and the absolute risk remains relatively low for most patients
Employer-sponsored coverage expansion Corporate coverage for GLP-1 medications shows measurable growth patterns
SeekPeptides members get access to detailed protocols that account for these variables, but whether you're researching independently or seeking guided support, understanding these mechanisms is essential
Jasmine P